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ABSTRACT 
Objective: The present work aimed to synthesize some new 1, 3-diheterocyles indolyl derivatives and study their cytotoxic activity. In addition, 
explore the probability of the most promising antiproliferative compounds to inhibit TopoI enzyme theoretically via molecular docking study. 
Methods: Reaction of ethyl 2-(3-formyl-1H-indol-1-yl)acetate (1) with 2-cyanoacetic acid hydrazide, 3-amino-5-pyrazolone and 2'-acetyl-2-
cyanoacetohydrazide in an equal molar ratio led to the formation of compounds 2, 6, 8 and 10, respectively, which in turn reacted with another 
molecule of 2-cyanoacetic acid hydrazide and/or 3-amino-5-pyrazolone (1:1 molar ratio) to give novel series of 1,3-dipyrazole indole derivatives 3, 
7, 9 and 11, respectively. On the other hand, Knoevenagel condensation of 1 with malononitrile gave ethyl 2-(3-(2, 2-dicyanovinyl)-1H-indol-1-yl) 
acetate (11). Reaction of 11 with 2-cyanoacetic acid hydrazide, 3-amino-5-pyrazolone, hydrazine hydrate, urea, thiourea and/or guanidine yielded 
1, 6-diaminopyridine 12, pyrano(2,3-c)pyrazole 14, pyrazole 16 and pyrimidine derivatives 18a-c, respectively. Reaction of the latter compounds 
with 3-amino-5-pyrazolone furnished a novel series of 1, 3-diheterocycle indole derivatives 13, 15, 17 and 19a-c, respectively. Ten new target 
compounds 3, 6, 8, 10, 13, 15, 17 and 19a-c were tested for in vitro antiproliferative activity against A-549, MCF7, HCT-116 and HEPG2 cancer cell 
lines. In addition, molecular docking study of the most promising antiproliferative compounds against human DNA Topoisomerase I (PDB ID: 1T8I) 
theoretically is discussed. 
Results: Compounds 3, 6, 8 and 17 showed potent in vitro antiproliferative activity. Docking scores of the latter compounds were observed better 
than co-crystalline ligand.  
Conclusion: Further work is recommended to confirm the inhibition of TopoI in a specific bioassay. 
Keywords: Ethyl 2-(3-formyl-1H-indol-1-yl) acetate, Pyrazole, Pyrimidine Anticancer, Molecular docking.  
 
INTRODUCTION 
Nitrogen-containing heterocyclic molecules constitute the largest 
portion of chemical entities, which represented a part of many 
natural products and biologically active compounds [1]. Indole 
which is the potent basic pharmacodynamic nucleus has been 
reported to possess a wide variety of biological properties viz, anti-
inflammatory [2, 3], anti-cancer [4, 5], antimicrobial [6, 7], and 
antioxidant [8]. In particular, N-1 and C-3-substituted indole 
derivatives have been found to play an important role in many 
biologically active compounds especially with anticancer activity 
[9,10]. Additionally, literature revealed that pyrazole, pyridine and 
pyrimidine are known for their pronounced pharmaceutical 
activities [11-13]. DNA topoisomerase I (TopoI) are eukaryotic 
ubiquitous enzymes that can relax negative and positive supercoiled 
DNA by breaking a single strand of the DNA duplex to prevent 
excessive supercoiling. The essential roles of these enzymes are 
regulating the topological rearrangement of DNA during 
transcription, replication and recombination. Therefore, these 
enzymes have been identified as important targets for cytotoxic 
drugs and their inhibitors are widely used for decades in cancer 
chemotherapy [14]. However, emerging tumor resistance and 
several side effects, such as haematological toxicity, nausea, 
vomiting, and hear loss are associated with TopoI inhibitors [14]. So, 
the discovery of new type TopoI inhibitors that can be synthesized 
easily, show increased sensitivity in drug resistant tumors and 
decreased dose-limiting toxicity would be a significant addition to 
the choices available in the treatment of cancer.  
Based on the previous observations and in continuation of our 
search on the preparation of new 3-indolyl heterocycles derivatives 
with anticancer activity [3-6, 10], the present work is designed to 
prepare new heterocyclic compounds incorporated to the indole 
moiety and evaluating their cytotoxic activity in a trial of obtaining 
new compounds with high activity and less toxicity. In addition, we 
attempted to explore the probability of the most promising 
antiproliferative compounds to inhibit TopoI enzyme theoretically 
via molecular docking study of these compounds against the active 
site of the protein molecular surface of human DNA Topoisomerase I 
(PDB ID: 1T8I). 
MATERIALS AND METHODS 
General 
Melting points were determined on the digital melting point 
apparatus (Electrothermal 9100, Electrothermal Engineering Ltd, 
serial No. 8694, Rochford, United Kingdom) and are uncorrected. 
The micro analytical data were achieved on a Perkin-Elmer 2400 
analyzer (Perkin-Elmer, 940 Winter Street, Waltham, Massachusetts 
02451, USA) and were found within±0.4 % of the theoretical values. 
IR spectra were recorded on a Perkin-Elmer 1600 Fourier 
Transform Infrared Spectrophotometer using KBr discs. The NMR 
spectra were measured with a Bruker Avance digital spectrometer 
(BRUKER BioSpin GMBH Silberstreifen D-76287 Rheinstetten, 
Germany) (500 MHz for 1H and 125 MHz for [13]C) in DMSO-d6, and 
chemical shifts were recorded in δ ppm relative to TMS as internal 
standard (all NH2 and NH recorded for the compounds were D2O-
exchangeable). Mass spectra (EI) were recorded at 70eV with JEOL-
JMS-AX500 mass spectrometer (JEOL Ltd. 1-2, Musashino 3-chome 
Akishima, Tokyo 196-8558, Japan). All reagents and solvents were of 
commercial grade. Ethyl 2-(3-formyl-1H-indol-1-yl) acetate (1) [15], 
2-cyanoacetic acid hydrazide [16], 3-amino-5-pyrazolone [17] and 
2'-acetyl-2-cyanoacetohydrazide [18] were prepared as reported.  
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indol-1-yl) acetate (2) 
A mixture of ethyl 2-(3-formyl-1H-indol-1-yl)acetate (1) (2.31 g, 
0.01 mol) and 2-cyanoacetic acid hydrazide (0.99 g, 0.01 mol) in 
absolute ethanol (15 ml) containing few drops of glacial acetic acid 
was heated under reflux for 3h. The solid formed on hot were 
filtered off, washed with ethanol, air dried and crystallized from 
acetic acid. Yield: 80%; MP: 182-184˚C; IR (KBr) υ 3265, 3185 (NH), 
2207 (CN), 1705, 1679 (C=O), 1565 (C=C), 1172, 1138 cm-1 (C-O-
C);1H NMR (500 MHz, DMSO-d6): δ 1.21 (3H, t, CH3), 4.21 (2H, q, 
CH2), 5.18 (2H, s, CH2-N), 7.20–7.48 (4H, m, Ar-H), 8.32 (1H, s, 
indolyl H-2), 11.38, 11.43 ppm (2H, 2s, 2NH); MS: (m/z) 310 [M+, 
30%]; Anal. C16H14N4O3 (310.31): Calcd: C, 61.93; H, 4.55; N, 18.06; 
Found: C, 61.77; H, 4.35; N, 18.22. 
5-Amino-1-(3-(4-cyano-2,3-dihydro-3-oxo-1H-pyrazol-5-yl)-1H-
indol-1-yl)acetyl)-1,2-dihydropyrazol-3-one (3) 
To a solution of sodium (0.23 g, 0.01 mol) in absolute methanol (20 
ml) was added compound 2 (3.1 g, 0.01 mol) and 2-cyanoacetic acid 
hydrazide (0.99 g, 0.01 mol). The reaction mixture was heated under 
reflux for 3h. After cooling the solid that formed was filtered off, 
washed with water, air dried and crystallized from absolute ethanol. 
Yield: 81%; MP: 204-206˚C; IR (KBr) υ 3412 (NH2), 3328, 3241, 
3165 (3NH), 2210 (CN), 1715, 1695, 1653 (C=O), 1566 cm-1 (C=C); 
1H NMR (500MHz, DMSO-d6): δ 5.17 (2H, s, CH2-N), 5.31 (1H, s, 
pyrazolyl H-4), 6.55-7.37 (4H, m, Ar-H), 8.06 (1H, s, indolyl H-2), 
8.40 (2H, s, NH2), 8.27, 9.69, 9.93 ppm (3H, 3s, 3NH); 13C NMR 
(125MHz, DMSO-d6): δ 48.2 (CH2), 117.6 (CN), 118.2-147.1 (Ar-C), 
170.1, 182.6 and 206.9 ppm (C=O); MS: (m/z) 363 [M+, 33%]; Anal. 
C17H13N7O3 (363.33): Calcd: C, 56.20; H, 3.61; N, 26.99; Found: C, 
56.44; H, 3.55; N, 27.06. 
Ethyl 2-(3-(2-cyano-3-hydrazinyl-3-oxoprop-1-enyl)-1H-indol-
1-yl) acetate (4) 
A mixture of 1 (2.31 g, 0.01 mol) and 2-cyanoacetic acid hydrazide 
(0.99 g, 0.01 mol) in absolute ethanol (15 ml) and triethylamine (1 
ml) was stirred at room temperature for 2h. The solid that formed 
was filtered off, washed with ethanol, air dried and crystallized from 
acetic acid. Yield: 75%; MP: 128-130˚C; IR (KBr) υ 3407, 3322 (NH2), 
3245 (NH), 2205 (CN), 1710, 1662 (C=O), 1565 (C=C), 1110, 1128 
cm-1 (C-O-C); 1H-NMR (500MHz, DMSO-d6): δ 1.21 (3H, t, CH3), 2.65 
(2H, s, NH2), 4.18 (2H, q, CH2), 5.23 (2H, s, CH2-N), 7.12-7.81 (4H, m, 
Ar-H), 8.17 (1H, s, CH=C), 8.32 (1H, s, indolyl H-2), 9.43 ppm (1H, s, 
NH); MS: (m/z): 312 [M+, 23%]; Anal. C16H16N4O3 (312.32): Calcd: C, 
61.53; H, 5.16; N, 17.94; Found: C, 61.42; H, 5.22; N, 17.81. 
Ethyl 2-(3-(3-amino-5-oxo-1H-pyrazol-4(5H)-ylidene) methyl)-
1H-indol-yl)acetate (5) 
Method A: Compound 4 (3.12 g, 0.01 mol) was heated under reflux 
in absolute ethanol (15 ml) containing triethylamine (3 ml) for 3h. 
After cooling, the solid that formed was filtered off, air dried and 
crystallized from absolute ethanol. 
Method B: A mixture of compound 1 (2.31 g, 0.01 mol) and 2-
cyanoacetic acid hydrazide (0.99 g, 0.01 mol) in absolute ethanol 
and triethylamine (3 ml) was heated under reflux for 3h. After 
cooling, the solid that formed was filtered off, air dried and 
crystallized from absolute ethanol. Yield: 80%; MP: 190-192˚C; IR 
(KBr) υ 3420 (NH2), 3273 (NH), 1697, 1638 (C=O), 1618 (C=N), 
1535 (C=C), 1106, 1132 cm-1 (C-O-C); 1H NMR (500MHz, DMSO-d6): δ 
1.21 (3H, t, CH3), 2.71 (2H, s, NH2), 4.16 (2H, q, CH2), 5.02 (2H, s, CH2-
N), 7.17-8.02 (5H, m, Ar-H and CH=C), 8.25 (1H, s, indolyl H-2), 10.03 
ppm (1H, s, NH); MS: (m/z) 312 [M+, 18%]; Anal. C16H16N4O3 




To a solution of sodium (0.23 g, 0.01 mol) in absolute methanol (20 
ml) was added compound 5 (3.12 g, 0.01 mol) and 3-amino-5-
pyrazolone (0.99 g, 0.01 mol). The reaction mixture was heated 
under reflux for 3h. After cooling the solid that formed was filtered 
off, air dried and crystallized from absolute ethanol. Yield: 65%; MP: 
378dec ˚C; IR (KBr) υ 3367, 3286, 3225 (NH2 and NH), 1715, 1692, 
1665 (C=O), 1617 (C=N), 1533 cm-1 (C=C); 1H NMR (500MHz, DMSO-
d6): δ 2.62 (2H, s, NH2), 4.24 (2H, s, CH2 pyrazole), 5.17 (2H, s, CH2-N), 
6.01 (1H, s, NH), 7.21-8.15 (5H, m, Ar-H and CH=C), 8.52 (1H, s, 
indolyl H-2), 8.73 and 10.02 ppm (2H, 2s, NH);[13]C NMR (125MHz, 
DMSO-d6): δ 49.97 and 56.53 (2CH2), 111.5-153.3 (Ar-C), 168.6 and 
183.47 (C=O); MS: (m/z) 365 [M+, 35%]; Anal. C17H15N7O3 (365.35): 
Calcd: C, 55.89; H, 4.14; N, 26.84; Found: C, 56.00; H, 4.22; N, 26.66. 
Ethyl 2-(3-(4,5-dihydro-5-oxo-1H-pyrazol-3-yl)methylene 
amino)-1H-indol-1-yl) acetate (7) 
A mixture of 1 (2.31 g, 0.01 mol) and 3-amino-5-pyrazolone (0.99 g, 
0.01 mol) in absolute ethanol (15 ml) containing few drops of glacial 
acetic acid was heated under reflux for 3h. The solid formed on hot 
were filtered off, washed with ethanol, air dried and crystallized 
from acetic acid. Yield: 82%; MP: 130-132˚C; IR (KBr) υ 3246 (NH), 
1683, 1652 (C=O), 1618 (C=N), 1538 (C=C), 1107,1128 cm-1 (C-O-C); 
1H NMR (500MHz, DMSO-d6): δ 1.23 (3H, t, CH3), 4.12 (2H, q, CH2), 
4.22 (2H, s, CH2 pyrazole), 5.03 (2H, s, CH2-N), 7.17-7.45 (4H, m, Ar-
H), 8.21 (1H, s, indolyl H-2), 8.54 (1H, s, CH=N), 10.32 ppm (1H, s, 
NH); MS: (m/z) 312 [M+, 42%]; Anal. C16H16N4O3 (312.32): Calcd: C, 




To a solution of sodium (0.23 g, 0.01 mol) in absolute methanol (20 
ml) was added compound 7 (3.12 g, 0.01 mol) and 3-amino-5-
pyrazolone (0.99 g, 0.01 mol). The reaction mixture was heated 
under reflux for 3h. After cooling the solid formed was filtered off, 
washed with water, air dried and crystallized from absolute ethanol. 
Yield: 70%; MP: 270dec ˚C; IR (KBr) υ 3375, 3285, 3169 (NH), 1712, 
1667 (C=O), 1620 (C=N), 1563 cm-1 (C=C);1H NMR (500MHz, DMSO-
d6): δ 4.18, 4.25 (4H, 2s, 2CH2 pyrazole), 5.13 (2H, s, CH2-N), 7.05-
7.46 (5H, m, Ar-H and NH), 8.32 (1H, s, indolyl H-2), 8.56 (1H, s, 
CH=N), 9.05 and 10.16 ppm (2H, 2s, 2NH);[13]C NMR (125MHz, 
DMSO-d6): δ 47.7, 52.6 and 61.5 (3CH2), 107.1-169.7 (Ar-C), 184.6 
and 206.9 (C=O); MS: (m/z) 365 [M+, 24%]; Anal. C17H15N7O3 
(365.35): Calcd: C, 55.89; H, 4.14; N, 26.84; Found: C, 55.99; H, 4.22; 
N, 26.95. 
Ethyl 2-(3-(1-acetyl-5-imino-3-oxopyrazolidin-4-ylidene) 
methyl)-1H-indol-1-yl) acetate (9) 
A mixture of compound 1 (2.31g, 0.01 mol) and 2'-acetyl-2-
cyanoacetohydrazide (1.41 g, 0.01 mol) in absolute ethanol (15 ml) 
containing triethylamine (1 ml) was heated under reflux for 3h. The 
solid formed on hot was filtered off, washed with ethanol, air dried 
and crystallized from absolute ethanol. Yield: 71%; MP: 268-270˚C; 
IR (KBr) υ 3285, 3173 (NH), 1705, 1675 (C=O), 1620 (C=N), 1585 
(C=C), 1110, 1138 cm-1 (C-O-C); 1H NMR (500MHz, DMSO-d6): δ 1.24 
(3H, t, CH3), 2.04 (3H, s, COCH3), 4.26 (2H, q, CH2), 5.27 (2H, s, CH2-
N), 7.17-8.04 (5H, m, Ar-H and CH=C), 8.45 (1H, s, indolyl H-2), 9.21 
and 10.02 ppm (2H, 2s, 2NH); MS: (m/z) 354 [M+, 31%]; Anal. 
C18H18N4O4 (354.36): Calcd: C, 61.01; H, 5.12; N, 15.81; Found: C, 




To a solution of sodium (0.23 g, 0.01 mol) in absolute methanol (20 
ml) was added compound 9 (3.54 g, 0.01 mol) and 3-amino-5-
pyrazolone (0.99 g, 0.01 mol). The reaction mixture was heated 
under reflux for 3h. After cooling the solid formed was filtered off, 
washed with water, air dried and crystallized from absolute ethanol. 
Yield: 65%; MP: 101-103˚C; IR (KBr) υ 3365, 3229 (NH), 1705, 1685, 
1665 (C=O), 1618 (C=N), 1525 cm-1 (C=C); 1H NMR (500MHz, DMSO-
d6): δ; 2.14 (3H, s, COCH3), 4.84 (2H, s, CH2-N), 5.46 (2H, 2s, 2NH), 
7.16-7.92 (5H, m, Ar-H and CH=C), 8.35 (1H, s, indolyl H-2), 8.72 and 
9.56 ppm (2H, 2s, 2NH); MS: (m/z) 407 [M+, 39%]; Anal. C19H17N7O4 
(407.38): Calcd: C, 56.02; H, 4.21; N, 24.07; Found: C, 56.22; H, 4.35; 
N, 24.07. 
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Ethyl 2-(3-(2,2-dicyanovinyl)-1H-indol-1-yl)acetate (11) 
A mixture of compound 1 (2.31 g, 0.01 mol) and malononitrile (0.66 
g, 0.01 mol) in absolute ethanol (10 ml) and few drops of piperidine 
was stirred for 30 min at room temperature. The precipitate that 
formed was filtered off, washed with absolute ethanol, air dried and 
crystallized from absolute ethanol. Yield: 85%; MP: 181-183˚C; IR 
(KBr) υ 2207 (CN), 1675 (CO), 1612 cm-1 (C=C); 1H NMR (500MHz, 
DMSO-d6): δ 1.21(3H, t, CH3), 4.16 (2H, q, CH2), 5.42 (2H, s, CH2), 
7.26-8.04 (3H, m, Ar-H), 8.50 (1H, s, CH=C), 8.57 (1H, s, indolyl H-4), 
8.70 ppm (1H, d, indolyl H-4); MS: (m/z) 279 [M+, 55%]; Anal. 
C16H13N3O2 (279.29): Calcd: C, 68.81; H, 4.69; N, 15.05; Found: C, 
68.76; H, 4.59; N, 15.20. 
Ethyl 2-(3-(1,6-diamino-1,2-dihydro-2-oxo-3,5-dicyano-pyridin-
4-yl)-1H-indol-1-yl)acetate (12) 
A mixture of compound 11 (2.79 g, 0.01 mol) and 2-cyanoacetic acid 
hydrazide (0.99 g, 0.01 mol) in absolute ethanol (20 ml) and few 
drops of piperidine was heated under reflux for 7h. After cooling the 
solid that formed was filtered off, air dried and crystallized from 
absolute ethanol. Yield: 70%; MP: 376-378˚C; IR (KBr) υ 3422, 3375 
(NH2), 2207 (CN), 1702, 1665 (C=O), 1543 (C=C), 1102, 1133 cm-1 
(C-O-C); 1H NMR (500MHz, DMSO-d6): δ 1.15 (3H, t, CH3), 2.61 (2H, s, 
NH2), 4.18 (2H, q, CH2), 5.21 (2H, s, CH2-N), 6.25 (2H, s, NH2), 7.21-
8.16 (4H, m, Ar-H), 8.57 (1H, s, indolyl H-2); MS: (m/z) 376 [M+, 
20%]; Anal. C19H16N6O3 (376.37): Calcd: C, 60.63; H, 4.28; N, 22.33; 




To a solution of sodium (0.23 g, 0.01 mol) in absolute methanol (20 
ml) was added compound 12 (3.54 g, 0.01 mol) and 3-amino-5-
pyrazolone (0.99 g, 0.01 mol). The reaction mixture was heated 
under reflux for 3h. After cooling the solid that formed was filtered 
off, washed with water, air dried and crystallized from absolute 
ethanol. Yield: 60%; MP: 234 dec ˚C; IR (KBr) υ 3445 (NH2), 3260, 
3225, 3164 (NH), 2210 (CN), 1705, 1675 (C=O), 1552 (C=C), 1618 
cm-1 (C=N); 1H NMR (500MHz, DMSO-d6): δ 2.65 (2H, s, NH2), 4.02 
(2H,s, CH2 pyrazole), 5.17 (2H, s, CH2-N), 6.04 (2H, s, NH2), 7.12-7.85 
(4H, m, Ar-H), 8.35 (1H, s, indolyl H-2), 8.76 and 9.52 ppm (2H, 2s, 
2NH); MS: (m/z) 429 [M+, 11%]; Anal. C20H15N9O3 (429.39): Calcd: C, 
55.94; H, 3.52; N, 29.36; Found: C, 55.99; H, 3.49; N, 29.29. 
Ethyl 2-(3-(3,6-diamino-5-cyanopyrano(2,3-c)pyrazol-4-yl)-1H-
indol-1-yl)acetate (14) 
A mixture of 11 (2.79 g, 0.01 mol) and 3-amino-5-pyrazolone (0.99 g, 
0.01 mol) in absolute ethanol (15 ml) and few drops of piperidine 
was heated under reflux for 3h. The solid formed on hot were 
filtered off, washed with ethanol, air dried and crystallized from 
ethanol-water (10:1). Yield: 45%; MP: 236-238˚C; IR (KBr) υ 3425, 
3362 (NH2), 2205 (CN), 1675 (C=O), 1552 (C=C), 1115, 1138 cm-1 (C-
O-C); 1H NMR (500MHz, DMSO-d6): δ 1.21 (3H, t, CH3), 2.16 (2H, s, 
NH2), 4.16 (2H, q, CH2), 5.16 (2H, s, CH2-N), 6.01 (2H, s, NH2), 7.21-
8.02 (4H, m, Ar-H), 8.45 ppm (1H, s, indolyl H-2); MS: (m/z) 376 [M+, 
27%]; Anal. C19H16N6O3 (376.37): Calcd: C, 60.63; H, 4.28; N, 22.33; 
Found: C, 60.54 H, 4.22; N, 22.29. 
N-(4,5-Dihydro-5-oxo-1H-pyrazol-3-yl)-2-(3-(3,6-diamino-5-cyano-
pyrano(2,3-c) pyrazol-4-yl)-1H-indol-1-yl)acetamide (15) 
To a solution of sodium (0.23 g, 0.01 mol) in absolute methanol (20 
ml) was added compound 14 (3.76 g, 0.01 mol) and 3-amino-5-
pyrazolone (0.99 g, 0.01 mol). The reaction mixture was heated 
under reflux for 3h. After cooling the solid that formed was filtered 
off, air dried and crystallized from absolute ethanol. Yield: 60%; MP: 
233dec ˚C; IR (KBr) υ 3426, 3328 (NH2), 3255, 3172 (NH), 2197 
(CN), 1685, 1652 (C=O), 1618 (C=N), 1536 (C=C), 1110, 1128 cm-1 
(C-O-C); 1H NMR (500MHz, DMSO-d6): δ 2.29 (2H, s, NH2), 4.91 and 
6.99 (4H, 2s, 2CH2), 7.11-8.31 (5H, m, Ar-H), 8.72 (2H, s, NH2), 10.31 
ppm (2H, s, 2NH); [13]C NMR (125MHz, DMSO-d6): δ48.2 (CH2), 
115.4 (CN), 109.1-147.9 (Ar-C), 170.1 and 206.5 (C=O); MS: (m/z) 
429 [M+, 10%]; Anal. C20H15N9O3 (429.39): Calcd: C, 55.94; H, 3.52; N, 
29.36; Found: C, 55.99; H, 3.66; N, 29.44. 
Ethyl 2-(3-(3,5-diamino-pyrazol-4(5H)-ylidene)methyl)-1H-
indol-1-yl)acetate (16) 
A mixture of 11 (2.79 g, 0.01 mol) and hydrazine hydrate (0.5 ml, 
0.01 mol) in absolute ethanol (15 ml) and the few drops of 
piperidine was heated under reflux for 3h. The solid formed on hot 
were filtered off, washed with ethanol, air dried and crystallized 
from ethanol. Yield: 77%; MP: 224-226˚C; IR (KBr) υ 3454, 3360 
(NH2), 1665 (C=O), 1618 (C=N), 1525 (C=C), 1109, 1125 cm-1 (C-O-
C); 1H NMR (500MHz, DMSO-d6): δ 1.29 (3H, t, CH3), 2.17 and 2.64 
(4H, 2s, 2 NH2), 4.20 (2H, q, CH2), 5.32 (2H, s, CH2), 7.19-8.11 (4H, m, 
Ar-H), 8.42 (1H, s, CH=C), 8.51 ppm (1H, s, indolyl H-2); MS: (m/z) 
311 [M+, 42%]; Anal. C16H17N5O2 (311.34): Calcd: C, 61.72; H, 5.50; N, 
22.49; Found: C, 61.67; H, 5.44; N, 22.35. 
N-(4,5-Dihydro-5-oxo-1H-pyrazol-3-yl)-2-(3-(3,5-diamino-
pyrazol-4(5H)-ylidene) methyl)-1H-indol-1-yl)acetamide (17)  
To a solution of sodium (0.23 g, 0.01 mol) in absolute methanol (20 
ml) was added compound 16 (3.11 g, 0.01 mol) and 3-amino-5-
pyrazolone (0.99 g, 0.01 mol). The reaction mixture was heated 
under reflux for 3h. After cooling the solid that formed was filtered 
off, air dried and crystallized from absolute ethanol. Yield: 65%; MP: 
190-192˚C; IR (KBr) υ 3440 (NH2), 3236, 3165 (NH), 1675, 1654 
(C=O), 1618 (C=N), 1517 cm-1 (C=C); 1H NMR (500MHz, DMSO-d6): δ 
2.16 and 2.64 (4H, 2s, 2NH2), 4.01 (2H, s, CH2 pyrazole), 5.17 (2H, s, 
CH2-N), 6.88 (1H, s, NH), 7.29-8.15 (5H, m, Ar-H and CH=C), 8.51 (1H, 
s, indolyl H-2), 10.52 ppm (1H, s, NH);[13]C NMR (125MHz, DMSO-
d6): δ 31.1 and 48.3 (2CH2), 111.3-148.1 (Ar-C), 170.1 and 183.1 ppm 
(C=O); MS: (m/z) 364 [M+, 29%]; Anal. C17H16N8O2 (364.36): Calcd: C, 
56.04; H, 4.43; N, 30.75; Found: C, 56.01; H, 4.31; N, 30.65. 
Ethyl 2-(3-(4,6-diamino-2-oxopyrimidin-5-ylidene)methyl)-1H-
indol-1-yl)acetate (18a)  
A mixture of 11 (2.79 g, 0.01 mol) and urea (0.6 g, 0.01 mol) in 
absolute ethanol (20 ml) and few drops of glacial acetic acid was 
heated under reflux for 3h. After cooling the solid that formed 
was filtered off, air dried and crystallized from absolute ethanol. 
Yield: 70%; MP: 195-197˚C; IR (KBr) υ 3450, 3272 (NH2), 1703, 
1673 (C=O), 1575 (C=C), 1105, 1132 cm-1 (C-O-C); 1H NMR 
(500MHz, DMSO-d6): δ 1.24 (3H, t, CH3), 1.95 (4H, s, 2NH2), 4.16 
(2H, q, CH2), 5.27 (2H, s, CH2-N), 7.17-8.21 (5H, m, Ar-H and 
CH=C), 8.55 ppm (1H, s, indolyl H-2); MS: (m/z) 339 [M+, 36%]; 
Anal. C19H17N5O3 (339.35): Calcd: C, 60.17; H, 5.02; N, 20.64; 
Found: C, 60.29; H, 5.11; N, 20.59. 
Ethyl 2-(3-(4,6-diamino-2-thioxopyrimidin-5-ylidene)methyl)-
1H-indol-1-yl) acetate (18b) 
A mixture of compound 11 (2.79 g, 0.01 mol) and thiourea (0.76 g, 
0.01 mol) in absolute ethanol (15 ml) and few drops of glacial acetic 
acid was heated under reflux for 3h. After cooling, the solid that 
formed was filtered off, air dried and crystallized from absolute 
ethanol. Yield: 71%; MP: 183-185˚C; IR (KBr) υ 3401, 3212 (NH2), 
1662 (C=O), 1526 (C=C), 1240 (C=S), 1112, 1142 cm-1 (C-O-C); 1H 
NMR (500MHz, DMSO-d6): δ 1.33 (3H, t, CH3), 2.61 (4H, s, 2NH2), 
4.22 (2H, q, CH2), 5.26 (2H, s, CH2), 7.12-7.46 (4H, m, Ar-H), 7.54 (1H, 
s, CH=C), 8.24 ppm (1H, s, indolyl H-2); MS: (m/z) 355 [M+, 26%]; 
Anal. C19H17N5O2S (355.41): Calcd: C, 57.45; H, 4.82; N, 19.70; Found: 
C, 57.39; H, 4.99; N, 19.69.  
Ethyl 2-(3-(4,6-diamino-2-iminopyrimidin-5-ylidene)methyl)-
1H-indol-1-yl) acetate (18c) 
A mixture of 11 (2.79 g, 0.01 mol), guanidine hydrochloride 
(0.69 g, 0.01 mol) and sodium acetate (0.82g, 0.01 mol) in 
absolute ethanol (15 ml) was heated under reflux for 3h. After 
cooling the solid that formed was filtered off, air dried and 
crystallized from absolute ethanol. Yield: 65%; MP: 134dec ˚C; IR 
(KBr) υ 3443, 3378 (NH2), 3221 (NH), 1656 (C=O), 1621 (C=N), 
1569 (C=C), 1125, 1106 cm-1 (C-O-C); 1H-NMR (500MHz, DMSO-
d6): δ 1.21 (3H, t, CH3), 2.21 (1H, s, NH), 2.61 (4H, s, 2NH2), 4.14 
(2H, q, CH2), 5.05 (2H, s, CH2-N), 7.07-7.85 (5H, m, Ar-H and 
CH=C), 8.53 ppm (1H, s, indolyl H-2); MS: (m/z) 338 [M+, 30%]; 
Anal. C19H18N6O2 (338.36): Calcd: C, 60.34; H, 5.36; N, 24.84; 
Found: C, 60.29; H, 5.29; N, 24.99. 
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Preparation of compounds 19a, 19b and 19c  
To a solution of sodium (0.23 g, 0.01 mol) in absolute methanol (20 
ml) was added compound 18a, 18b or 18c (0.01 mol) and 3-amino-
5-pyrazolone (0.99 g, 0.01 mol). The reaction mixture was heated 
under reflux for 3h. After cooling the solid that formed was filtered 
off, air dried and crystallized from absolute ethanol. 
N-(4,5-Dihydro-5-oxo-1H-pyrazol-3-yl)-2-(3-(4,6-diamino-2-oxo-
pyrimidin-5-ylidene)methyl)-1H-indol-1-yl)acetamide (19a) 
Yield: 66%; MP: 222dec ˚C; IR (KBr) υ 3428, 3327 (NH2), 3226, 3195 
(NH), 1705, 1653 (C=O), 1624 (C=N), 1554 cm-1 (C=C); 1H NMR 
(500MHz, DMSO-d6): δ 2.23 (4H, s, 2NH2), 3.92 (2H, s, CH2 pyrazole), 
5.06 (2H, s, CH2-N), 6.25 (1H, s, NH), 7.02-7.75 (5H, m, Ar-H and 
CH=C), 8.17 (1H, s, indolyl H-2), 8.72 ppm (1H, s, NH);[13]C NMR 
(125MHz, DMSO-d6): δ 61.5 and 66.34 (2CH2), 106-147.9 (Ar-C), 
168.8, 184.2 and 206.4 ppm (C=O); MS: (m/z) 392 [M+, 42%]; Anal. 
C18H16N8O3 (392.37): Calcd: C, 55.10; H, 4.11; N, 28.56; Found: C, 




Yield: 70%; MP: 366-368˚C; IR (KBr) υ 3400, 3228 (NH2), 3197 (NH), 
1685 (C=O), 1618 (C=N), 1590 (C=C), 1245 cm-1 (C=S); 1H NMR 
(500MHz, DMSO-d6): δ 2.12 (4H, s, 2NH2), 4.02 (2H, s, CH2 pyrazole), 
5.11 (2H, s, CH2-N), 6.25 (1H, s, CH=C), 7.15-7.82 (4H, m, Ar-H), 8.25 
(1H, s, indolyl H-2), 8.54 and 9.37 ppm (2H, 2s, NH); [13]C NMR 
(125MHz, DMSO-d6): δ 61.5 and 66.34 (2CH2), 107.1-169.7 (Ar-C), 
184.6 and 206.9 ppm (C=O); MS: (m/z) 408 [M+, 23%]; Anal. 
C18H16N8O2S (408.44): Calcd: C, 52.93; H, 3.95; N, 27.43; Found: C, 




Yield: 56%; MP: 378-380˚C; IR (KBr) υ 3424, 3321 (NH2), 3221, 
3165 (NH), 1676 (C=O), 1622 (C=N), 1545 cm-1 (C=C); 1H NMR 
(500MHz, DMSO-d6): δ 2.61 (4H, s, 2NH2), 5.22 and 5.29 (4H, 2s, 
2CH2), 7.10-7.67 (5H, m, Ar-H and C=NH), 8.09 (1H, s, CH=C), 8.41 
(1H, s, indolyl H-2), 8.60 and 9.34 ppm (2H, 2s, 2NH); [13]C NMR 
(125MHz, DMSO-d6): δ 47.7 and 61.5 (2CH2), 107-148.4 (Ar-C), 169.2 
and 184.6 ppm (C=O);MS: (m/z) 391 [M+, 16%]; Anal. C18H17N9O2 




A-549 (human lung cancer), MCF7 (human breast cancer) and HCT-
116 (human colon cancer) and MCF7 (human breast cancer) cell 
lines were obtained from Karolinska Institute, Stockholm, Sweden. 
All cells were maintained in RPMI 1640 medium, except for A-549 
cancer cells which were maintained in DMEM medium (Lonza 
Biowahittkar, Belgium). All the media were supplemented with 1% 
antibiotic-antimycotic mixture (10,000 U ml-1 potassium penicillin, 
10,000 µg ml-1streptomycin sulfate, 25µg ml-1 amphotericin B and 
1% L-glutamine (Biowest, USA).  
MTT cytotoxicity assay 
Cell viability was investigated using MTT [3-(4, 5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide] (Bio Basic Canada Inc., 
Canada) assay [19]. This reaction depends on the mitochondrial 
reduction of yellow MTT into purple formazan. All the preceding 
steps were carried out in sterile laminar air flow cabinet Biosafety 
class II level (Baker, SG403INT; Sanford, ME, USA). All incubations 
were done at 37˚C in 5% CO 2 incubator in the humidified 
atmosphere (Sheldon, TC2323; Cornelius, OR, USA). Cells were 
seeded into 96-well microtiter plastic plates at the concentration of 
(104 cells per well) and allowed to adhere for 24 hours. Medium was 
aspirated and fresh medium (without serum) was added to the cells 
with various concentrations of the test compounds (100, 50, 25, 
12.5, 6.25, 3.12, 1.56 and 0.78µg ml-1 in DMSO) and incubated for 48 
hours. The medium was aspirated and 40 µl MTT salt (2.5µg ml-1) 
was added to each well and incubated for a further 4 hours. To stop 
the reaction and dissolve any formed formazan crystals, 200 µl of 
10% sodium dodecyl sulfate (SDS) were added to each well and 
incubated overnight at 37̊C.  The amount of formazan product was 
measured at 595 nm with a reference wavelength of 620 nm as a 
background using a microplate reader (Bio-Rad Laboratories, model 
3350, USA). For the untreated cells (negative control), medium was 
added instead of the test compounds. A positive control 
Adrinamycin® (doxorubicin) (Mr=579.9) was used as a known 
cytotoxic natural agent giving 100% inhibition. Dimethyl sulfoxide 
(DMSO) was the vehicle used for dissolution of testing compound 
and its final concentration on the cells was less than 0.2%. IC50 was 
calculated for the samples and negative control (cells with vehicle) 
by the probit analysis using a simple t-test (SPSS statistical analysis 
software package/version 11.0, SPSS Inc., (IL), Chicago, USA).  
Molecular docking study 
Docking study of the most active antiproliferative compounds 3, 6, 8 
and 17 were performed by Molecular Operating Environment (MOE) 
2008.10 releases of Chemical Computing Group, Montereal, Canada 
(http://www. chemcomp. com.). The program operated on an 
Intel(R) core(TM) i3-32100 CPU@3.10GHz 3.09 GHz processor, 3.41 
GB of RAM, Microsoft Windows XP.  
Docking was performed against to the active site of the protein 
molecular surface of TopoI (PDB ID: 1T8I). The protein crystal 
structure of human DNA Topoisomerase I (PDB ID: 1T8I) in complex 
with camptothecin (4-ethyl-4-hydroxy-1, 12-dihydro-4H-2-oxa-6, 12a-
diaza-dibenzo [b, h] fluorene-3, 13-dione) was downloaded from 
protein data bank (http://www. rcsb. org/-pdb) (PDB ID: 1T8I) [20].  
The protein crystal structure was prepared for docking via removing 
of water molecules, addition and removal of polar hydrogen atoms 
then isolation of the active pocket. The active site was considered to 
be the site where co-crystalline ligand namely, camptothecin 
complexes with human DNA Topoisomerase I (PDB ID: 1T8I). The 
active pocket consisted of 20 amino acid residues as THR (D718), 
B12, TGP (B11), ASN (D722 and D352), ASP (D533), DT (A9, A19), 
DC (C112), LYS (D354, D532, D436, and D751), ARG (D364), DA 
(C113), GLU (D356), TRP (D416), MET (D428), TYR (D426) 
The co-crystalline ligand was re-docked in the active pocket to 
insure the docking method was efficient and the active pocket was 
saved as moe file to be used for docking simulation of the selected 
compounds (ligands).  
The structure of the selected compounds (ligands) for docking was 
drawn in ChemDraw Ultra 10.0 (ChemOffice package) and saved as 
mol. Before the molecular docking, preparation steps must be done 
as follow; a) converting the 2D structure of ligands to their 3D form; 
b) addition and removing of polar hydrogen atoms; c) energy 
minimized using the MMFF94x force field until a RMSD (Root-mean-
square deviation) of atomic position gradient of 0.01 Kcal mol-1 Å-1 
was reached and saved as moe. MMFF94x was reported as the 
efficient force field for minimizing ligand-protein complexes [21]. 
The docking Algorithm was done by MOE-DOCK default. It uses 
flexible, rigid technique for posing the molecule inside the cavity. All 
rotatable bonds of ligands are allowed to undergo free rotation to be 
placed into the rigid receptor binding site. The docking scores were 
expressed in negative energy terms; the lower the binding free 
energy, the better the binding affinity [22],and the ligand 
interactions (hydrogen bonding and hydrophobic interaction) with 
human DNA Topoisomerase I was determined. 
RESULTS AND DISCUSSION 
Chemistry 
The synthetic routes of the target compounds are outlined in 
Schemes 1, 2 and 3. Condensation of ethyl 2-(3-formyl-1H-indol-1-
yl) acetate (1) with 2-cyanoactic acid hydrazide in an equal molar 
ratio (1:1) in absolute ethanol containing a few drops of glacial 
acetic acid under reflux furnished a main product identified as ethyl 
2-(3-(4-cyano-2,3-dihydro-3-oxo-1H-pyrazol-5-yl)-1H-indol-1-yl) 
acetate (2). 1H NMR spectrum of 2 revealed triplet and quartet 
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signals at δ 1.21 and 4.21 ppm, respectively, due to the ester group 
in addition to the singlet signal at δ 5.18 ppm which attributed to 
CH2N, also revealed signals at δ 11.43 and 11.38 ppm due to the NH 
protons (D2O-exchangeable), besides the aromatic protons. Its mass 
spectrum showed a molecular ion peaks at m/z (%) = 310 (30). The 
pathway of the formation of 2 may initially start with the formation 
of aldemine A followed by intramolecular cyclization and 
aromatization to give 2, Scheme 1. 
Further reflux of compound 2 with another molecule of 2-
cyanoacetic acid hydrazide (1:1 molar ratio) in methanol and in the 
presence of sodium methoxide afforded a product identified as 5-
amino-1-(3-(4-cyano-2,3-dihydro-3-oxo-1H-pyrazol-5-yl)-1H-indol-
1-yl)acetyl)-1,2-dihydropyrazol-3-one (3). 1H NMR spectrum of 3 
lacked the presence of ester protons of compound 2 and revealed 
new signals at δ 9.93, 9.69, 8.27 and 8.40 ppm due to (3H, 3NH and 
2H, NH2, D2O-exchangeable), respectively, in addition to singlet 
signals at δ 8.06, 5.31 and 5.17 ppm due to indolyl H-2 pyrazolyl H-4 
and CH2N, respectively, besides the aromatic protons at δ 7.37-6.55 
ppm. Its mass spectrum showed a molecular ion peak at m/z (%) = 
363(33). The pathway of the formation of 3 may initially start with 
the reaction between basic N-amino group of 2-cyanoacetic acid 
hydrazide and ester group with the loss of a molecule of ethanol, 
followed by nucleophilic addition of the lone pair of NH and CH2 to 
cyano group B to give 3, Scheme 1. 
 
 
Scheme 1: Synthesis of compounds 2 and 3 
 
Base catalyzed reaction of 1 with 2-cyanoacetic acid hydrazide (1:1 
molar ratio) under stirring at room temperature in absolute ethanol 
afforded ethyl 2-(3-(2-cyano-3-hydrazinyl-3-oxoprop-1-enyl)-1H-
indol-1-yl)acetate (4), which on heating under reflux in absolute 
ethanol containing few drops of triethylamine yielded the cyclic 3-
amino-5-oxo-1H-pyrazole derivative 5 (method A), Scheme 2. The 
absence of absorption band of (CN) in IR spectrum of compound 5 
confirmed the intramolecular cyclization of compound 4.  
On the other hand, base catalyzed reaction of compound 1 with 3-
amino-5-pyrazolone (1:1 molar ratio) under reflux in absolute 
ethanol yielded a product identical in all aspects (mp, TLC, IR and 1H 
NMR spectra) with compound 5 with good yield 80% (method B), 
Scheme 2.  
Further reflux of compound 5 with another molecule of 3-amino-5-
pyrazolone (1:1 molar ratio) in methanol and in the presence of sodium 
methoxide led to the formation of N-(4,5-dihydro-5-oxo-1H-pyrazol-3-
yl)-2-(3-(3-amino-5-oxo-1H-pyrazol-4(5H)-ylidene) methyl)-1H-indol-
yl)acetamide (6), Scheme 2. 
Acid catalyzed reaction of compound 1 with 3-amino-5-pyrazolone 
(1:1 molar ratio) under reflux in absolute ethanol yielded the 
corresponding Schiff base 7, which on reaction with another 
molecule of 3-amino-5-pyrazolone (1:1 molar ratio) in methanol and 
in the presence of sodium methoxide led to the formation of N-(4,5-
dihydro-5-oxo-1H-pyrazol-3-yl)-2-(3-(4,5-dihydro-5-oxo-1H-pyrazo 
l -3-yl) methyleneamino)-1H-indol-1-yl)acetamide (8).  
On the other hand, reaction of compound 1 with 2'-acetyl-2-
cyanoacetohydrazide in absolute ethanol gave a product identified 
as ethyl 2-(3-(1-acetyl-5-imino-3-oxopyrazolidin-4-ylidene)methyl)-
1H-indol-1-yl)acetate (9). IR spectrum of 9 showed the absence of 
CN group. It's 1H NMR spectrum revealed singlet signal at δ 2.04 
ppm due to COCH3 in addition, two singlet signals at δ 10.02, 9.21 
ppm of 2NH protons (D2O-exchangeable). Treatment of compound 9 
with 3-amino-5-pyrazolone (1:1 molar ratio) in methanol and in the 
presence of sodium methoxide led to the formation of N-(4,5-
dihydro-5-oxo-1H-pyrazol-3-yl)-2-(3-(1-acetyl-5-imino-3-oxo-










































































































 Scheme 2: Synthesis of compounds 4-10 
Knoevenagel condensation of compound 1 with malononitrile under 
stirring in absolute ethanol at room temperature gave ethyl 2-(3-(2, 2-
dicyanovinyl)-1H-indol-1-yl) acetate (11). Cyclocondensation of 11 with 
2-cyanoacetic acid hydrazide in the presence of piperidine led to the 
formation of 1,6-diaminopyridine derivative 12, whereas 
cyclocondensation of 11 with 3-amino-5-pyrazolone afforded 
pyrano(2,3-c) pyrazole derivative 14. Treatment of compounds 12 and 
14 with 3-amino-5-pyrazolone (1:1 molar ratio) in methanol and in the 




1H-indol-1-yl)acetamide (15), respectively, Scheme 3. 
On the other hand, reaction of 11 with hydrazine hydrate under reflux in 
ethanol in the presence of triethylamine afforded ethyl 2-(3-(3,5-
diaminopyrazol-4(5H)-ylidene)methyl)-1H-indol-1-yl) acetate (16), 
which on treatment with 3-amino-5-pyrazolone (1:1 molar ratio) in 
methanol and in the presence of sodium methoxide led to the 
formation of N-(4,5-dihydro-5-oxo-1H-pyrazol-3-yl)-2-(3-(3,5-
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diamino-pyrazol-4(5H)-ylidene)methyl)-1H-indol-1-yl)acetamide 
(17), Scheme 3. Finally, reaction of 11 with urea, thiourea or 
guanidine in absolute ethanol under reflux led to the formation of 4, 
6-diamino-2-oxopyrimidine 18a, 4,6-diamino-2-thioxopyrimidine 
18b and 4,6-diamino-2-iminopyrimidine derivatives 18c, 
respectively. Further reaction of the latter compounds with 3-
amino-5-pyrazolone (1:1 molar ratio) in methanol and in the 
presence of sodium methoxide led to the formation of 1, 3-





























































































































18 & 19, a, X=O
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Scheme 2: Synthesis of compounds 11-19 
 
Cytotoxic activity 
Ten new compounds numerically labeled with 3, 6, 8, 10, 13, 15, 17, 
19a, 19b and 19c were preliminary screened for their in vitro 
antiproliferative activity against human lung cancer (A-549), human 
liver cancer (HEPG2), human colon cancer (HCT-116) and human 
breast cancer (MCF7) cell lines at a concentration of 100µg ml-
1(table 1). Compounds 3, 6, 15, 17, 19b and 19c showed potent 
antiproliferative activity against A-549 cancer cell line of 100, 100, 
97.3, 100, 100 and 80.0%, respectively, whereas, compounds 3 and 8 
showed activity of 100% against HEPG2, and only compound 8 
showed activity of 100% against HCT-116. On the other hand, 
compounds 15, 17, 19a and 19c showed antiproliferative activity of 
100, 100, 92.3 and 100% against MCF7 (table 1). 
 
Table 1: Antiproliferative activity of the newly synthesized compounds against human carcinoma cell lines at 100µg ml-1 
Compound a Inhibition growth (%) (mean±SEM) 
A549 HEPG2 HCT116 MCF7 
3 100±0.00 100±0.00 15.9±1.20 65.9±1.20 
6 100±0.00 29.8±1.60 27.6±1.66 35.8±2.60 
8 42.3±1.20 100±0.00 100±0.00 22.5±3.50 
10 53.8±1.45 33.2±2.60 3.8±0.60 29.4±1.70 
13 64.5±2.16 28.7±1.10 21.5±1.00 26.8±3.80 
15 97.3±1.15 38.5±2.20 27.6±2.60 100±0.00 
17 100±0.00 26.9±1.30 16.9±1.30 100±0.00 
19a 62.7±3.90 29.7±2.30 26.8±1.70 92.3±1.50 
19b 100±0.00 44.5±1.95 18.5±2.70 100±0.00 
19c 80.0±2.08 11.8±1.28 35.4±2.00 57.4±3.70 
Negative controlb 0 0 0 0 
Doxorubicina 100±0.00 100±0.00 100±0.00 100±0.00 
aconcentration of test compounds and positive control (doxorubicin) were 100µg ml-1, bUntreated cells in DMSO and its final concentration in the 
cells was less than 0.2 %, SEM = Standard error mean; each value is the mean of three values. 
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Compounds that showed antiproliferative activity higher than 80% 
at concentration of 100µg ml-1were used to calculate their IC50 value, 
which corresponds to the concentration required for 50% inhibition 
of cell viability. Doxorubicin, which is one of the most effective 
anticancer agents, was used as a reference drug (table 2). In case of 
A-549 cancer cell line, compound 3, 6 and 17 revealed potent 
activity of IC50 of 42.8, 44.9 and 45.8 µM, respectively, higher than 
the reference drug doxorubicin of IC50 48.8 µM. Regarding HEPG2 
cell line, the results indicated that compounds 6 and 8 showed 
potent activity with IC50 of 68.5 and 23.1 µM, respectively, higher 
than the reference drug doxorubicin with IC50 of 37.8 µM. The results 
of HCT116 cell line indicated that only compound 8 has potent effect 
with IC50 of 57.4 µM higher than the reference drug doxorubicin of 
IC50 65.1µM. 
 
Table 2: IC50 of the highly antiproliferative active compounds against human cancer cell lines 
Compounds 
 
IC50 (mean±SEM) (µM) 
A549 HEPG2 HCT116 MCF7 
3 42.8±2.10 - - 72.5±3.10 
6 44.9±3.20 68.5±2.10 - 92.3±2.30 
8 105.5±1.90 23.1±3.50 57.4±2.70 110.1±3.50 
15 90.1±3.50 - - - 
17 45.8±2.60 - - - 
19a - - - - 
19b - - - 128.2±5.6 
19c 149.1±2.10 - - - 
Doxorubicin 48.8±1.30 37.8±1.50 65.1±1.00 45.0±2.20 
IC50: Compound concentration required to inhibit the cell viability by 50%, SEM = Standard error mean; each value is the mean of three values 
 
Molecular docking study  
The most promising antiproliferative compounds 3, 6, 8 and 17 were 
employed in docking study toward human DNA Topoisomerase I 
(PDB ID: 1T8I) using MOE 2008.10 program.  From the data 
obtained (table 3, fig. 1a,b-5a,b) it was found that, the compounds 
under study exhibited good fitting inside the binding site of the 
protein molecular surface and having minimum binding energy 
ranged from-17.71 to-22.09kJ mol-1in comparison to co-crystallized 
ligand. Co-crystallized ligand camptothecin (4-ethyl-4-hydroxy-1,12-
dihydro-4H-2-oxa-6, 12a-diaza-dibenzo[b, h] fluorene-3, 13-dione) 
exhibited binding energy of-17.61kJ mol-1,  
RMSD value of 0.71 and formed two hydrogen bond; a) N atom of 
the quinoline ring with C=N of ARG (D364) in distance 2.85 Å; b) 
OH group of the pyrone ring with OH of ASP (D533) in distance 
2.71 Å, besides two arene-arene links between quinoline ring 
and DA (C113) (table 3, fig. 1a,b). 
 












-17.61 N of quinoline C=N of ARG (D364) 2.85 
OH of pyrone OH of ASP (D533) 2.71 
Ph DA (C113) arene-arene 
Pyridine DA (C113) arene-arene 
3 -22.09 NH NH of DA (B13) 3.18 
NH OH of DG (B12) 3.18 
CN NH of ARG (D364) 3.20 
NH NH of THR (D718) 2.66 
6 -21.13 C=O NH of LYS (D435) 2.50 
NH OH of TYR (D426) 2.72 
NH2 OH of LYS (D354) 2.76 
8 -19.04 NH OH of DG (B12) 2.32 
NH OH of ASP (D533) 2.42 
Indole DA (C113) arene-arene 
Indole TGP (B11) arene-arene 
17 -17.71 NH NH of DG (B12) 3.37 
NH NH of DA (B13) 2.80 
NH of pyrazole C=O of ASN (D722) 2.72 
Indole ARG (D364) II-arene 
 
  
Fig. 1b: Simplified structure showing interaction between 
camptothecin and the amino acid residues in the human DNA TopoI 
(PDB ID: 1T8I) active site 
Fig. 1a: Docked conformation alignment of co-crystallized 
ligand (camptothecin) in the human DNA TopoI (PDB ID: 1T8I) 
binding site 
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Compound 3 in which NH of indole was protected with acetyl 
pyrazole-5-amine moiety; besides the presence of pyrazole-4-
carbonitrile ring at C-3 of indole showed the best docking score 
with minimum binding energy of-22.09 kJ mol-1 and formed four 
H-bonds with the amino acid residues of TopoI; a) NH2 of the 
acetyl pyrazole ring with NH of DA (B13) and OH of DG (B12) in 
distance 3.18 and 3.18Å, respectively; b) CN of the pyrazole-4-
carbonitrile with NH of ARG (D364) in distance 3.20Å; c) NH of 
the pyrazole-4-carbonitrile with NH of THR (D718) in distance 
2.66Å (fig. 2a, b). 
 
  
Fig. 2b: Simplified structure showing interaction between 3 and 
the amino acid residues in the human DNA TopoI (PDB ID: 1T8I) 
active site 
Fig. 2a: Docked conformation alignment of 3 and its original co-
crystallized ligand in the human DNA TopoI (PDB ID: 1T8I) 
binding site 
  
By replacement of N-(acetyl pyrazole-5-amine) with N-(acetamidopyrazole) in compound 6; besides the presence of pyrazolone ring moiety at C-3 
of indole via methylidene bridge kept the good fitting inside the pockets site of the protein molecular surface with binding energy of-21.13 kJ mol-1 
and formed three H-bonds; a) C=O of the acetamidopyrazole with NH of LYS (D435) in distance 2.50 Å; b) NH of the aminopyrazolone ring with OH 
of TYR (D426) in distance 2.72 Å; NH2 of the aminopyrazolone ring with OH of LYS (D354) in distance 2.76 Å (fig. 3a, b). 
 
  
Fig. 3b: Simplified structure showing interaction between 6 and 
the amino acid residues in the human DNA TopoI (PDB ID: 1T8I) 
active site 
Fig. 3a: Docked conformation alignment of 6 and its original co-
crystallized ligand in the human DNA TopoI (PDB ID: 1T8I) 
binding site 
  
On the other hand, compound 8 in which pyrazole ring linked to indole moiety via methylene amino bridge showed binding energy of-19.04 kJ 
mol-1 and formed two H-bonds; a) NH of the pyrazole ring with OH of DG (B12) in distance 2.32 Å; b) NH of the acetamido group with OH of ASP 
(D533) in distance 2.42 Å, beside two arene-arene links between indole moiety with DA(C113) and TGP(B11), respectively (fig. 4a, b). 
 
  
Fig. 4b: Simplified structure showing interaction between 8 and the 
amino acid residues in the human DNA TopoI (PDB ID: 1T8I) active 
site 
Fig. 4a: Docked conformation alignment of 8 and its original co-
crystallized ligand in the human DNA TopoI (PDB ID: 1T8I) 
binding site 
 
The presence of 3,5-diaminopyrazole ring incorporate to indole moiety at C-3 via methylidene bridge in compound 17 showed binding energy of-
17.71 kJ mol-1 nearly similar to co-crystallized ligand camptothecin with three H-bonds; a) NH2 of 3,5-diamino-pyrazole ring with NH of DG (B12) in 
distance 3.37 Å and NH of DA (B13) in distance 2.80 Å; b) NH of the pyrazole ring with C=O of ASN (D722) in distance 2.72 Å, beside one II-arene 
link between indole ring and ARG (D364) (fig. 5a, b). 
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Fig. 5b: Simplified structure showing interaction between 17 
and the amino acid residues in the human DNA TopoI (PDB ID: 
1T8I) active site 
Fig. 5a: Docked conformation alignment of 17 and its original co-
crystallized ligand in the human DNA TopoI (PDB ID: 1T8I) binding 
site 
 
These results of cytotoxic activity and molecular docking suggest 
that, substituted 1,3-dipyrazolylindole derivatives may have 
potential for development as clinical candidates to treat a variety of 
solid tumors. 
CONCLUSION 
New series of 1, 3-diheterocycles indole derivatives were 
synthesized starting from ethyl 2-(3-formyl-1H-indol-1-yl) acetate. 
Ten new compounds 3, 6, 8, 10, 13, 15, 17 and 19a-c were tested for 
in vitro antiproliferative activity against A-549, MCF7, HCT-116 and 
HEPG2 cancer cell lines. The potent antiproliferative compounds 3, 
6, 8 and 17 were employed for docking study towards human DNA 
Topoisomerase I (PDB ID: 1T8I). The result showed that, the docking 
scores of the compounds under study were observed better than co-
crystalline ligand (camptothecin), which was in agreement with 
their antiproliferative effects. Further work is recommended to 
confirm the inhibition of TopoI in a specific bioassay. 
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